Dominik Chraniuk

Provincial Polyclinical Hospital in Toruń — Poland

Medicine · Health Sciences

6h-index198citations23works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(10), Myeloproliferative Neoplasms: Diagnosis and Treatment(10), Chronic Lymphocytic Leukemia Research(8), Multiple Myeloma Research and Treatments(4), Lymphoma Diagnosis and Treatment(3)

Publications23 total

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study
Blood·2025Open Access
Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study
Blood·2025Open Access
An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
Blood·2025Open Access
MPN-794: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor-Naive Patients With Myelofibrosis: 72-Week Follow-Up With Long-Term Efficacy Outcomes of the Phase 3 Manifest-2 Study
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MPN-794 Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor-Naive Patients With Myelofibrosis: 72-Week Follow-Up With Long-Term Efficacy Outcomes of the Phase 3 Manifest-2 Study
Clinical Lymphoma Myeloma & Leukemia·2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Nature Medicine·2025· 17 citedOpen Access
Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis
Blood·2024· 6 cited
River-52: A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Blood·2024· 1 citedOpen Access
P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2024· 2 cited
MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Clinical Lymphoma Myeloma & Leukemia·2024
Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Clinical Lymphoma Myeloma & Leukemia·2024
Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.
Journal of Clinical Oncology·2024· 7 cited
Abstract CT144: Safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma
Cancer Research·2024
Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology·2024
A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Blood·2023· 3 cited
Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3
Blood·2023· 4 cited
Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Blood·2023· 28 cited
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
The Lancet Haematology·2023· 113 cited
Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.
Journal of Clinical Oncology·2023
Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Blood·2021· 2 cited
page 1 of 2Next →

Frequent Co-authors

Raajit K. Rampal(9), Sebastian Grosicki(9), Elisabetta Abruzzese(9), Prithviraj Bose(9), Aaron T. Gerds(9), Francesca Palandri(9), Sung‐Eun Lee(9), Alessandro Lucchesi(9), Andrew Kuykendall(9), Ruben A. Mesa(9), Jean‐Jacques Kiladjian(9), Moshe Talpaz(9), John Mascarenhas(9), Stephen T. Oh(8), Andrea Patriarca(8), Vikas Gupta(7), Alessandro M. Vannucchi(6), Morgan Harris(6), Barbara Brown(6), David Lavie(6)